Ed Amer, a counsel in Goodwin's Private Equity Group, represents private equity and venture capital firms, investors and private companies in a broad range of business and financing transactions. His practice focuses primarily on private equity acquisitions and dispositions, venture capital financings, mergers and acquisitions, start-up company counseling and general corporate representation. Prior to pursuing a career in law, Mr. Amer worked as a lighting technician in the motion picture industry.




Mr. Amer’s work for clients has included representing and/or advising:

  • Ampersand Capital Partners and 1315 Capital in their acquisition of Genoptix, Inc., a provider of comprehensive testing solutions in hematology and solid tumor molecular profiling, from Novartis Pharmaceuticals Corporation.
  • The sale of Agilux Laboratories, Inc., an Ampersand Capital Partners portfolio company, to Charles River Laboratories International, Inc.
  • Ampersand Capital Partners in its acquisition of a majority stake in Corpus Medical, a provider of consulting and manufacturing services for development and commercialization of interventional medical devices.
  • Florida Biologix in its merger with Brammer Biopharmaceuticals LLC, forming Brammer Bio, LLC, a cell and gene therapy biologics contract development and manufacturing organization. 
  • Avista Pharma in its acquisition of the GMP contract manufacturing, development and animal health services business of Scynexis, Inc. (NASDAQ: SCYX).
  • Nitinol Devices and Components, Inc. (“NDC”) in its acquisition of Interface Catheter Solutions (“Interface”). NDC is the largest contract manufacturer of nitinol-based medical devices and Interface is a pioneer is medical balloon technology and the leading contract manufacturer of balloon catheter systems. Following the acquisition, NDC and Interface created Confluent Medical Technologies, a leading contract manufacturer of specialized medical devices.
  • Ampersand Capital Partners in its acquisition of Protein Technologies, a maker of peptide synthesizers and reagents.*
  • Accuratus Lab Services, an Ampersand Capital Partners portfolio company, in its acquisition of the chemistry, manufacturing and control testing services business of Array BioPharma.*
  • United Recovery Systems, an Audax Group portfolio company, in the bolt-on acquisitions of Enterprise Recovery Systems, Financial Health Strategies and Array Services Group.*
  • NutraMed, an Ampersand Capital Partners portfolio company, in its acquisition of Nutritional Laboratories International.*
  • Tyrogenex and Xcovery, two affiliated drug-development companies, as general counsel and in a number of financing transactions.*
  • Ampersand Capital Partners in its minority investment in CutisPharma, an industry leader in prescription compounding pharmaceuticals.*
  • ChanTest Corporation, a leading private equity backed provider of specialized laboratory testing services for drug development, in its acquisition by Charles River Laboratories.*
  • ViraCor-IBT Laboratories, Inc., a premier specialty diagnostics laboratory, as general counsel, in several bolt-on acquisitions, and in its acquisition by Eurofins Scientific for a purchase price of approximately $255 million.*
  • CRI Lifetree, a clinical research service provider, in its acquisition by clinical research organization PRA Health Sciences, a KKR portfolio company.*
  • Magellan Biosciences in the sale of its microbiology testing products division, TREK Diagnostic Systems, to Thermo Fischer Scientific.*
  • A syndicate of investors, including MPM Capital and Oxford Bioscience Partners, in its investment in Radius Health.*
  • Ampersand Capital Partners and SV Life Sciences in the acquisition of a controlling interest in CRI Worldwide, a leading provider of clinical research services to the pharmaceutical industry.*
  • Novartis Venture Fund in its investments in drug development companies Tokai Pharmaceuticals and Aileron Therapeutics.*
  • MPM Capital and New Enterprise Associates in their investment in Rhythm, a biotechnology company developing peptide therapeutics for metabolic diseases.*
  • Ampersand Capital Partners in the leveraged buyout of K-TEK Corp., a leading global manufacturer of state-of-the-art level instrumentation for liquid and bulk solids detection.*
  • K-TEK Corp. in its sale to ABB, the global power and automation technology group.*

*Denotes experience prior to joining Goodwin.

Professional Experience

Prior to joining Goodwin in 2015, Mr. Amer was a partner at Locke Lord in Boston.


In law school, Mr. Amer served on the Boston College Law Review and was a member of the Order of the Coif.

In The News

In den Nachrichten






J.D., 2004
Boston College Law School

(magna cum laude)

B.A., 1992
Bowdoin College



Get In Touch
In Kontakt kommen
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.


Search Other Lawyers
Suche Andere Rechtsanwälte